Analyzing the impact of human leukocyte antigen mismatch on the incidence of prostate cancer and the advantage of T cell therapy in patients after kidney transplantation based on the United Network for Organ Sharing database

From the perspective of prostate cancer occurrence after transplantation, the use of T cell therapy is of great significance. HLA mismatch ≥ 3 was a risk factor of prostate cancer after KT. HLA-A and HLA-B 2-mismatch were risk factors of prostate cancer after KT, while HLA-DR 1-mismatch and 2-mismatch were both risk factors of prostate cancer after KT. This research contributed to the focus on the relationship between induction therapy and cancer occurrence after KT, and also provide guidance for reasonable selections of HLA typing of prostate cancer before KT.